ZA200307465B - Carbamate compounds for use in preventing or treating bipolar disorder. - Google Patents
Carbamate compounds for use in preventing or treating bipolar disorder. Download PDFInfo
- Publication number
- ZA200307465B ZA200307465B ZA200307465A ZA200307465A ZA200307465B ZA 200307465 B ZA200307465 B ZA 200307465B ZA 200307465 A ZA200307465 A ZA 200307465A ZA 200307465 A ZA200307465 A ZA 200307465A ZA 200307465 B ZA200307465 B ZA 200307465B
- Authority
- ZA
- South Africa
- Prior art keywords
- formula
- enantiomer
- substance
- composition
- predominates
- Prior art date
Links
- 208000020925 Bipolar disease Diseases 0.000 title claims description 54
- 150000004657 carbamic acid derivatives Chemical class 0.000 title description 4
- 238000000034 method Methods 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 59
- 150000001875 compounds Chemical class 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 32
- 238000011282 treatment Methods 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 25
- 230000002265 prevention Effects 0.000 claims description 24
- 125000000217 alkyl group Chemical group 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 239000000460 chlorine Substances 0.000 claims description 21
- 206010026749 Mania Diseases 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 19
- 229910052801 chlorine Inorganic materials 0.000 claims description 19
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 10
- 150000002367 halogens Chemical group 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 7
- -1 C.-C Chemical group 0.000 claims description 7
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 230000001351 cycling effect Effects 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 239000011630 iodine Substances 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 206010021030 Hypomania Diseases 0.000 claims description 3
- 208000028683 bipolar I disease Diseases 0.000 claims description 3
- 208000025307 bipolar depression Diseases 0.000 claims description 2
- 208000026725 cyclothymic disease Diseases 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims 31
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 230000001535 kindling effect Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 239000001961 anticonvulsive agent Substances 0.000 description 4
- 239000004050 mood stabilizer Substances 0.000 description 4
- 229940127237 mood stabilizer Drugs 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
- 229940102566 valproate Drugs 0.000 description 3
- 206010021118 Hypotonia Diseases 0.000 description 2
- 230000003556 anti-epileptic effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 229960003965 antiepileptics Drugs 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000036640 muscle relaxation Effects 0.000 description 2
- 230000001242 postsynaptic effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 206010018671 Grandiosity Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010064805 Tachyphrenia Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BQYRVMAWJCIIKI-UHFFFAOYSA-N carbamic acid;1-phenylethane-1,2-diol Chemical class NC(O)=O.OCC(O)C1=CC=CC=C1 BQYRVMAWJCIIKI-UHFFFAOYSA-N 0.000 description 1
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009945 mood elevation Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000003176 neuroleptic agent Substances 0.000 description 1
- 230000000701 neuroleptic effect Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27168101P | 2001-02-27 | 2001-02-27 | |
US10/081,766 US6562867B2 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating bipolar disorder |
PCT/US2002/005297 WO2002067921A1 (en) | 2001-02-27 | 2002-02-21 | Carbamate compounds for use in preventing or treating bipolar disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200307465B true ZA200307465B (en) | 2005-03-17 |
Family
ID=26765948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200307465A ZA200307465B (en) | 2001-02-27 | 2003-09-25 | Carbamate compounds for use in preventing or treating bipolar disorder. |
Country Status (27)
Country | Link |
---|---|
US (1) | US6562867B2 (ja) |
EP (1) | EP1408953B1 (ja) |
JP (1) | JP4276837B2 (ja) |
KR (1) | KR100946944B1 (ja) |
CN (1) | CN1250215C (ja) |
AT (1) | ATE324108T1 (ja) |
BR (1) | BR0207644A (ja) |
CA (1) | CA2439475C (ja) |
CY (1) | CY1105330T1 (ja) |
CZ (1) | CZ20032300A3 (ja) |
DE (1) | DE60210976T2 (ja) |
DK (1) | DK1408953T3 (ja) |
ES (1) | ES2262801T3 (ja) |
HK (1) | HK1063436A1 (ja) |
HU (1) | HUP0303243A3 (ja) |
IL (1) | IL157590A0 (ja) |
MX (1) | MXPA03007717A (ja) |
MY (1) | MY129304A (ja) |
NO (1) | NO20033802L (ja) |
NZ (1) | NZ527988A (ja) |
PL (1) | PL364638A1 (ja) |
PT (1) | PT1408953E (ja) |
RS (1) | RS50677B (ja) |
RU (1) | RU2300372C2 (ja) |
TW (1) | TWI250872B (ja) |
WO (1) | WO2002067921A1 (ja) |
ZA (1) | ZA200307465B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1305082E (pt) * | 2000-07-21 | 2004-09-30 | Ortho Mcneil Pharm Inc | Compostos de carbamato para utilizacao na prevencao ou tratamento da dor neuropatica e dor associada a cefaleia de salvas e enxaqueca |
CA2439286A1 (en) | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating anxiety disorders |
WO2002067925A1 (en) * | 2001-02-27 | 2002-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neurodegenerative disorders |
PL368164A1 (en) | 2001-07-16 | 2005-03-21 | Ortho-Mcneil Pharmaceutical, Inc. | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
EA200700642A1 (ru) * | 2004-09-16 | 2007-10-26 | Янссен Фармацевтика, Н. В. | Способы лечения эпилептогенеза и эпилепсии |
JP5024635B2 (ja) | 2005-06-08 | 2012-09-12 | エスケー バイオファーマスティカルズ カンパニー リミテッド | 睡眠覚醒障害の治療 |
US20070021501A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods of treating epileptogenesis |
EP2081648A2 (en) * | 2006-10-30 | 2009-07-29 | Janssen Pharmaceutica, N.V. | Carbamate compounds for use in treating depression |
CN101568333A (zh) * | 2006-10-31 | 2009-10-28 | 詹森药业有限公司 | 广泛性发育障碍的治疗 |
US8609849B1 (en) | 2010-11-30 | 2013-12-17 | Fox Chase Chemical Diversity Center, Inc. | Hydroxylated sulfamides exhibiting neuroprotective action and their method of use |
KR101717871B1 (ko) * | 2013-03-12 | 2017-03-20 | (주)바이오팜솔루션즈 | 페닐카바메이트 화합물 및 이를 포함하는 기억 손실-관련 질환의 예방 또는 치료용 조성물 |
US10195151B2 (en) | 2016-09-06 | 2019-02-05 | Jazz Pharmaceuticals International Iii Limited | Formulations of (R)-2-amino-3-phenylpropyl carbamate |
WO2018111008A1 (ko) * | 2016-12-14 | 2018-06-21 | 에스케이바이오팜 주식회사 | 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도 |
US10959976B2 (en) | 2017-06-02 | 2021-03-30 | Jazz Pharmaceuticals Ireland Limited | Methods and compositions for treating excessive sleepiness |
US10940133B1 (en) | 2020-03-19 | 2021-03-09 | Jazz Pharmaceuticals Ireland Limited | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3313692A (en) * | 1958-04-21 | 1967-04-11 | Armour Pharma | Method of inducing calming and muscle relaxation with carbamates |
US3278380A (en) * | 1962-02-06 | 1966-10-11 | Armour Pharma | Methods of calming employing diphenyl hydroxy carbamate compounds |
US3265728A (en) * | 1962-07-18 | 1966-08-09 | Armour Pharma | Substituted phenethyl carbamates |
US5698588A (en) * | 1996-01-16 | 1997-12-16 | Yukong Limited | Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol |
-
2002
- 2002-02-21 RU RU2003128997/14A patent/RU2300372C2/ru active
- 2002-02-21 MX MXPA03007717A patent/MXPA03007717A/es active IP Right Grant
- 2002-02-21 DK DK02724984T patent/DK1408953T3/da active
- 2002-02-21 AT AT02724984T patent/ATE324108T1/de active
- 2002-02-21 US US10/081,766 patent/US6562867B2/en not_active Expired - Lifetime
- 2002-02-21 IL IL15759002A patent/IL157590A0/xx not_active IP Right Cessation
- 2002-02-21 CA CA2439475A patent/CA2439475C/en not_active Expired - Fee Related
- 2002-02-21 DE DE60210976T patent/DE60210976T2/de not_active Expired - Lifetime
- 2002-02-21 JP JP2002567288A patent/JP4276837B2/ja not_active Expired - Lifetime
- 2002-02-21 KR KR1020037011296A patent/KR100946944B1/ko active IP Right Grant
- 2002-02-21 WO PCT/US2002/005297 patent/WO2002067921A1/en active IP Right Grant
- 2002-02-21 RS YUP-678/03A patent/RS50677B/sr unknown
- 2002-02-21 CN CNB028089170A patent/CN1250215C/zh not_active Expired - Fee Related
- 2002-02-21 PL PL02364638A patent/PL364638A1/xx not_active Application Discontinuation
- 2002-02-21 ES ES02724984T patent/ES2262801T3/es not_active Expired - Lifetime
- 2002-02-21 HU HU0303243A patent/HUP0303243A3/hu unknown
- 2002-02-21 EP EP02724984A patent/EP1408953B1/en not_active Expired - Lifetime
- 2002-02-21 PT PT02724984T patent/PT1408953E/pt unknown
- 2002-02-21 CZ CZ20032300A patent/CZ20032300A3/cs unknown
- 2002-02-21 BR BR0207644-6A patent/BR0207644A/pt not_active Application Discontinuation
- 2002-02-21 NZ NZ527988A patent/NZ527988A/en unknown
- 2002-02-27 TW TW091103500A patent/TWI250872B/zh active
- 2002-02-27 MY MYPI20020691A patent/MY129304A/en unknown
-
2003
- 2003-08-26 NO NO20033802A patent/NO20033802L/no not_active Application Discontinuation
- 2003-09-25 ZA ZA200307465A patent/ZA200307465B/en unknown
-
2004
- 2004-08-20 HK HK04106261A patent/HK1063436A1/xx not_active IP Right Cessation
-
2006
- 2006-06-21 CY CY20061100844T patent/CY1105330T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200307465B (en) | Carbamate compounds for use in preventing or treating bipolar disorder. | |
AU2002242226B2 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
AU2002247204B2 (en) | Carbamate compounds for use in preventing or treating movement disorders | |
AU2002242226A1 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
AU2002247204A1 (en) | Carbamate compounds for use in preventing or treating movement disorders | |
AU2002255580B2 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
AU2002354909B2 (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
AU2002255580A1 (en) | Carbamate compounds for use in preventing or treating bipolar disorder | |
AU2002354909A1 (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain | |
ZA200401155B (en) | Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain. |